Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/55854
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3502]
Metadata
Show full item record
IMMUNOCOMPROMISED PATIENTS HAVE BEEN NEGLECTED IN COVID-19 TRIALS: A CALL FOR ACTION
https://www.arca.fiocruz.br/handle/icict/53896
Author
Affilliation
Oslo University Hospital. Section of Clinical Immunology and Infectious Diseases. Oslo, Norway.
Geneva University Hospitals. HIV/AIDS Research Unit. Geneva, Switzerland.
Hospices Civils de Lyon. Hôpital de la Croix-Rousse. Département des Maladies Infectieuses et Tropicales. Lyon, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Hospital La Paz. Infectious Diseases Unit. Madrid, Spain.
Saint-Louis APHP. Infectious Diseases Department. Paris, France.
University Hospital. Division of Infectious Diseases. Zurich, Switzerland.
Cliniques Universitaires de Bruxelles-Hôpital Érasme. Université Libre de Bruxelles. Clinique des Maladies Infectieuses. Brussels, Belgium.
CHU de Bordeaux and Université de Bordeaux. Bordeaux, France.
Lausanne University Hospital. Infectious Diseases Service. Lausanne, Switzerland.
Sorbonne Université. Institut Pierre Louis d'Epidémiologie et de Santé Publique. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Oslo University Hospital. Section of Clinical Immunology and Infectious Diseases. Oslo, Norway.
Université de Paris. Paris, France.
Geneva University Hospitals. HIV/AIDS Research Unit. Geneva, Switzerland.
Geneva University Hospitals. HIV/AIDS Research Unit. Geneva, Switzerland.
Hospices Civils de Lyon. Hôpital de la Croix-Rousse. Département des Maladies Infectieuses et Tropicales. Lyon, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Hospital La Paz. Infectious Diseases Unit. Madrid, Spain.
Saint-Louis APHP. Infectious Diseases Department. Paris, France.
University Hospital. Division of Infectious Diseases. Zurich, Switzerland.
Cliniques Universitaires de Bruxelles-Hôpital Érasme. Université Libre de Bruxelles. Clinique des Maladies Infectieuses. Brussels, Belgium.
CHU de Bordeaux and Université de Bordeaux. Bordeaux, France.
Lausanne University Hospital. Infectious Diseases Service. Lausanne, Switzerland.
Sorbonne Université. Institut Pierre Louis d'Epidémiologie et de Santé Publique. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Oslo University Hospital. Section of Clinical Immunology and Infectious Diseases. Oslo, Norway.
Université de Paris. Paris, France.
Geneva University Hospitals. HIV/AIDS Research Unit. Geneva, Switzerland.
Abstract
Although several innovative and repurposed drugs have been approved for the treatment of COVID-19 during the last year, we still do not have evidence-based knowledge on the best therapeutic strategy to treat immunocompromised patients. Most treatment guidelines are structured to whether the disease state is mild, moderate, or severe, and not sufficiently according to host factors including host immunity. Whereas the Omicron variant causes less severe diseases in the general population, this is not necessarily the case for individuals with an impaired immune system, such as organ transplant recipients, patients with hematological malignancies, active cancer or primary immunodeficiency, or individuals treated with immunosuppressive drugs for a variety of medical conditions.
Share